InflaRx NV (IFRX)
1.34
-0.07
(-4.96%)
USD |
NASDAQ |
May 02, 15:55
InflaRx Cash from Financing (TTM): 57.36M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 57.36M |
September 30, 2023 | 60.11M |
June 30, 2023 | 60.22M |
March 31, 2023 | 2.178M |
December 31, 2022 | 2.043M |
September 30, 2022 | -0.0663M |
June 30, 2022 | -1.701M |
March 31, 2022 | -1.711M |
December 31, 2021 | 72.86M |
September 30, 2021 | 72.29M |
June 30, 2021 | 84.49M |
March 31, 2021 | 85.04M |
December 31, 2020 | 10.47M |
Date | Value |
---|---|
September 30, 2020 | 10.73M |
June 30, 2020 | 0.1557M |
March 31, 2020 | -0.3648M |
December 31, 2019 | -0.3295M |
September 30, 2019 | 0.6654M |
June 30, 2019 | -0.2561M |
March 31, 2019 | 58.56M |
December 31, 2018 | 58.62M |
September 30, 2018 | 179.18M |
June 30, 2018 | 180.30M |
March 31, 2018 | 121.62M |
December 31, 2017 | 123.22M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-1.711M
Minimum
Mar 2022
85.04M
Maximum
Mar 2021
27.06M
Average
2.178M
Median
Mar 2023
Cash from Financing (TTM) Benchmarks
Affimed NV | -6.734M |
MorphoSys AG | -- |
BioNTech SE | -842.92M |
Immatics NV | 91.50M |
CureVac NV | 249.97M |